


## TBOPP

## Chemical Properties

CAS No. :	1996629-79-8
Formula:	C <sub>24</sub> H <sub>21</sub> F <sub>3</sub> N <sub>2</sub> O <sub>4</sub> S
Molecular Weight:	490.49
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	TBOPP is a selective DOCK1 inhibitor (IC <sub>50</sub> : 8.4 μM), with anti-tumor activity for broader types of tumors.
Targets(IC <sub>50</sub> )	Others
In vitro	TBOPP as a selective inhibitor of DOCK1. TBOPP dampened DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins.
In vivo	TBOPP treatment suppressed cancer metastasis and growth in vivo in mice.

## Solubility Information

Solubility	DMSO: 120 mg/mL (244.65 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.16 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.0388 mL	10.1939 mL	20.3878 mL
5 mM	0.4078 mL	2.0388 mL	4.0776 mL
10 mM	0.2039 mL	1.0194 mL	2.0388 mL
50 mM	0.0408 mL	0.2039 mL	0.4078 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Tajiri H, et al. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCKCell Rep. 2017 May 2;19(5):969-980.

Feng J, Lu H, Ma W, et al. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Protein & Cell. 2022: 1-17.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481